HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prominent FDAer In Cosmetic Modernization Talks On Way Out

This article was originally published in The Rose Sheet

Executive Summary

Michael Taylor retires as deputy commissioner for foods and veterinary medicine on June 1, leaving behind a legacy of regulatory work under the Food Safety Modernization Act of 2010. Taylor also was a key figure in the agency's past negotiations with industry on a legislative plan to modernize cosmetics oversight, and his departure could be felt by FDA and other stakeholders if current legislation of that nature passes.

You may also be interested in...

Taylor Leaving FDA With Prevention As Food Safety Fundamental Strategy

Michael Taylor retires as deputy commissioner for foods and veterinary medicine on June 1 and will be succeeded by Stephen Ostroff, until recently FDA's acting commissioner and previously CFSAN's chief medical officer and senior public health advisor to Taylor.

Feinstein, EWG Gunning For Spring Senate Hearing On Cosmetics Bill

During a March 1 press call, the Environmental Working Group highlighted findings from an 800-person survey indicating that 68% of men and women likely to vote this fall support increased government oversight of cosmetic chemicals. Senator Dianne Feinstein touted her proposed Personal Care Products Safety Act as the answer to consumer concerns, hopeful that a Senate committee hearing will be held in the spring.

GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts